CSL (CSL) has said its new products are performing well, as it announced a rise in first-half profit.
The medical products supplier posted earnings before interest, tax, depreciation and amortisation of $US912 million in the six months to December 31, up from $US881 million in the previous corresponding half.
The result included a one-off anti-trust litigation settlement in the US totalling $US39 million after tax.
Net profit for the half was $US646 million, up from $US625 million in the first half of 2013.
“The company’s specialty products again performed exceptionally well,” CSL chief executive and managing director Paul Perreault said.
“We’ve also been able to remove the risk and associated distraction with the US anti-trust class action litigation.”
CSL will pay an unfranked interim dividend of US53 cents, or approximately AU59 cents per share, to shareholders on the record at March 12.